Public Board of Directors papers 27-10-22

1. To demonstrate excellent and equitable clinical outcomes and patient safety, patient experience and clinical effectiveness for those patients living with and beyond cancer Annual objective Measure Timescale Director Progress 1.5 Ensure patients receive excellent acute and supportive care Embed acute and supportive care directorate and clinical leadership 31.3.23 EMD On plan Develop Supportive Care strategy to align with Living with and beyond BRC bid On plan Expand ambulatory care capacity and implement virtual ward Complete 1.6 To deliver improvements to the patient environment & experience To deliver the 2022/23 Capital Plan in line with the ICS 31.3.23 EDoF On plan Transfer of the management of peripheral outpatient activity 31.3.23 COO On plan Implement the phase 1 of closed loop chemotherapy 31.3.23 COO On plan Enhance patient and staff experience in OP pharmacy services 31.3.23 COO On plan Explore the opportunities to improve patient facilities in CT 31.3.23 COO On plan 1.7 Improve information provided to patients around their cancer and treatment Implement the ‘Please, Write to Me’ guidance from the Academy of Medical Royal College across all clinical teams 31.3.23 EMD On plan

2. To be an international leader in research and innovation which leads to direct patient benefits at all stages of the cancer journey Annual objective Measure Timescale Director

Progress

2.1 Work in collaboration with regional, national and international research partners to provide world class cancer research

Refresh and embed new R&I strategy in alignment with other Christie clinical strategies and NIHR Biomedical Research Centre, Experimental Cancer Medicine Centre, Clinical Research Facility and CRUK Major Centre strategic objectives

On plan to deliver by end of the year

31.03.23 DCEO/DRI

Completion of the of the Paterson development

On plan

31.03.23

EDoF

20